Targeted cargo protein combination therapy

Abstract

The present invention combines a targeted cargo protein with an active agent for the treatment of a disease or condition.

1 - 20 . (canceled) 
     
     
         21 . A method of inhibiting a cancer cell that overexpresses an IL-4 receptor, comprising:
 a) contacting said cancer cell with a targeted cargo protein comprising a targeting moiety that specifically binds to an IL-4 receptor, and a cargo moiety that inhibits said cancer cell, and   b) contacting said cancer cell with an active agent.   
     
     
         22 . The method of  claim 21 , wherein said cancer cell is a cell of a cancer selected from the group consisting of brain cancer, a hematological cancer, Kaposi sarcoma, bladder cancer, renal cell cancer, breast cancer, pancreatic cancer, non-small cell lung cancer, thyroid cancer, squamous cell carcinoma of the head and neck, colon cancer, bile duct carcinoma, ovarian cancer, a cancer of the gastrointestinal system, mesothelioma, rhabdomyosarcoma, and prostate cancer. 
     
     
         23 . The method of  claim 22 , wherein said brain cancer cell is selected from the group consisting of a malignant astrocytoma cell, a medulloblastoma cell, a meningioma cell, and a glioma cell. 
     
     
         24 . The method of  claim 21 , wherein said active agent is selected from the group consisting of gemcitabine, doxorubicin, FOLFOX (folinic acid, fluorouracil, and oxaliplatin), premetrexed, irinotecan, temozolamide, cisplatin, oxaliplatin, erlotinib, imatinib, cetuximab, bevacizumab, and rituximab. 
     
     
         25 . A method of treating a cancer in a subject, cells of which cancer overexpress IL-4 receptors on their surface, comprising administering to said subject a targeted cargo protein in combination with an active agent,
 wherein said targeted cargo protein comprises a targeting moiety that specifically binds to an IL-4 receptor, and a cargo moiety comprising a BCL-2 pro-apoptotic related protein or a cytotoxin, and   wherein said active agent is a chemotherapeutic agent or a therapeutic antibody.   
     
     
         26 . The method of  claim 25 , wherein said cancer is selected from the group consisting of brain cancer, a hematological cancer, Kaposi sarcoma, bladder cancer, renal cell cancer, breast cancer, pancreatic cancer, non-small cell lung cancer, thyroid cancer, squamous cell carcinoma of the head and neck, colon cancer, bile duct carcinoma, ovarian cancer, a cancer of the gastrointestinal system, mesothelioma, rhabdomyosarcoma, and prostate cancer. 
     
     
         27 . The method of  claim 26 , wherein said brain cancer is selected from the group consisting of malignant astrocytoma, medulloblastoma, meningioma, and glioma. 
     
     
         28 . The method of  claim 25 , wherein said BCL-2 pro-apoptotic related protein is selected from the group consisting of BAX, BAD, BAT, BAK, BIK, BOK, BID, BIM, and BMF. 
     
     
         29 . The method of  claim 25 , wherein said active agent is selected from the group consisting of gemcitabine, doxorubicin, FOLFOX (folinic acid, fluorouracil, and oxaliplatin), premetrexed, irinotecan, temozolamide, cisplatin, oxaliplatin, erlotinib, imatinib, cetuximab, bevacizumab, and rituximab. 
     
     
         30 . The method of  claim 25 , wherein said cytotoxin is a  Pseudomonas  exotoxin. 
     
     
         31 . The method of  claim 25 , wherein said cytotoxin is modified  Pseudomonas  exotoxin A.